ライフサイエンスコーパス: matrix metalloproteinase

1 contribution of pericytes, immune cells, and matrix metalloproteinases.

2 and subsequent activation of intra-alveolar matrix metalloproteinases.

3 ese tumors also show upregulation of certain matrix metalloproteinases.

4 ediated, in part, by mechanisms dependent on matrix metalloproteinases.

5 ent of matrix-lytic enzymes, particularly of matrix metalloproteinases.

6 podia that act both to sequester and release matrix metalloproteinases.

7 mmatory mediators and increased synthesis of matrix metalloproteinases.

8 tory factors such as corneal microtrauma and matrix metalloproteinases.

9 d protein, protease-activated receptor-1, or matrix metalloproteinases.

10 inflammatory and pro-fibrotic cytokines and matrix metalloproteinases.

11 loid protein A [SAA]), inflammatory markers (matrix metalloproteinase 1 [MMP-1] and heme oxygenase 1

12 In mice, transgenic expression of human matrix metalloproteinase 1 causes caseous necrosis, the

13 tissue growth factor and tissue inhibitor of matrix metalloproteinase 1.

14 nic role of the cytokine tissue inhibitor of matrix metalloproteinases 1 (TIMP1) in primary pancreati

15 al telopeptide of collagen type I (CITP) and matrix metalloproteinase-1 (CITP:MMP-1) was determined i

16 RATIONALE: Matrix metalloproteinase-1 (MMP-1) and mast cells are pr

17 One factor, matrix metalloproteinase-1 (MMP-1), is induced in Drosop

18 nase (JNK)/AP-1 signaling, and expression of matrix metalloproteinase-1 (Mmp1) are activated downstre

19 raised reactive oxygen species production or matrix metalloproteinase-1, -2 and -9 activity nor decre

20 ndothelial growth factor, interleukin-1beta, matrix metalloproteinase-1, versican, and fibronectin.

21 ntibodies to endothelial cell growth factor, matrix metalloproteinase 10, and apolipoprotein B-100 in

22 n the active site of the catalytic domain of matrix metalloproteinase-12 (MMP-12 or macrophage metall

23 yte infiltration and increased expression of matrix metalloproteinase-12 and neutrophil elastase.

24 t the accumulation of macrophages expressing matrix metalloproteinase-12 started manifesting in glome

25 ivation-induced cytokine, CHI3L1, IL-16, and matrix metalloproteinase-12 were cardiovascular proteins

26 nd selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13).

27 The major metalloproteinase matrix metalloproteinase 13 (MMP13) is also associated w

28 xtracellular matrix (ECM) by the collagenase matrix metalloproteinase 13 (MMP13) represents a key eve

29 nocytes, but not axons, and up-regulation of matrix-metalloproteinase 13 (MMP-13, collagenase 3) in t

30 Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent

31 Furthermore, we identified a c-Met/ETS-1/matrix metalloproteinase-14 (MMP-14) axis that controls

32 f principle, we used the catalytic domain of matrix metalloproteinase-14 (MMP-14), a promalignant pro

33 tion decreases endothelial morphogenesis and matrix metalloproteinase-14 (MMP14) expression.

34 Then we identified matrix metalloproteinase 2 (MMP2) as a direct target of

35 ng is essential for the proper activation of matrix metalloproteinase 2 (Mmp2) for follicle rupture.

36 mals (P < 0.05), resulting in a reduction of matrix metalloproteinase 2 and 9 activity in resolvin-tr

37 , granulocyte colony-stimulating factor, and matrix metalloproteinase 2 in STZ-induced diabetic bone

38 rowth factor beta1, collagen type 4 alpha 1, matrix metalloproteinase 2, and alpha-smooth muscle acti

39 otein levels; increased expression of SNAIL, matrix metalloproteinase 2, and integrin beta1; and incr

40 ion, cellular retinol-binding protein 1, and matrix metalloproteinase 2, compared to term and preterm

41 ptor, vascular cell adhesion molecule 1, and matrix metalloproteinase 2, were significantly associate

42 of fibroblast activation markers, including matrix metalloproteinase 2, were significantly increased

43 with cellular retinol-binding protein 1 and matrix metalloproteinase 2.

44 -derived growth factor D, Pdgfrb, Itga2, and matrix metalloproteinases 2 and 9 expression in aortic l

45 17.8 [14.1-22.8] ng/mL) were higher, and for matrix metalloproteinase-2 (188 [155.5-230.6] ng/mL) low

46 Sensors showed a negligible response to matrix metalloproteinase-2 (MMP-2), a protease which may

47 TGF-beta1), connective tissue growth factor, matrix metalloproteinase-2 (MMP-2), MMP-14, endoglin (EN

48 B/urokinase-type plasminogen activator (uPA)/matrix metalloproteinase-2 (MMP-2).

49 In vitro, Meg3 regulated the production of matrix metalloproteinase-2 (MMP-2).

50 okinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2).

51 p, and Reck could suppress the expression of matrix metalloproteinase-2 (Mmp2) and Mmp9, which could

52 pendent mitochondrial Ca(2+) uptake promotes matrix metalloproteinase-2 activity and cell motility by

53 f ARF1 and Arfaptin2 leading to secretion of matrix metalloproteinase-2 and -7.

54 evels, reduced nitrosative stress, and lower matrix metalloproteinase-2 expression.

55 mice were unable to induce OX40 and OX40L by matrix metalloproteinase-2 on splenic dendritic cells.

56 eukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III N-terminal

57 n of phosphatidylserine (PS), annexin A6 and matrix metalloproteinase-2, which converts exosomes into

58 increased fibrosis and altered expression of matrix metalloproteinase-2.

59 lution in vivo using a fluorescent probe for matrix metalloproteinase-2/9 activity, fluorescein isoth

60 cided with the greatly reduced expression of matrix metalloproteinase 20 (MMP20) and kallikrein 4 (KL

61 l-length amelogenin undergoes proteolysis by matrix metalloproteinase 20 (MMP20, enamelysin) soon aft

62 o facilitate the biomimetic enamel regrowth, matrix metalloproteinase-20 (MMP-20) was introduced into

63 Matrix metalloproteinase-20 (MMP20) is expressed by amel

64 TWIST1 induced matrix metalloproteinase 3 (MMP3) expression without dir

65 iated with cGVHD, and only four (ST2, CXCL9, matrix metalloproteinase 3, and osteopontin) were necess

66 matory/prodestructive properties (e.g., IL-6/matrix metalloproteinase 3-release) in response to matri

67 though CAFs promoted prostate cancer growth, matrix metalloproteinase-3 (MMP-3) was lower in CAFs but

68 ression of late responsive genes such as the matrix metalloproteinase-3 and the RE1 silencing transcr

69 +) matrix resulted in the strongest IL-6 and matrix metalloproteinase-3 release, and was even more pr

70 Inactivation of RhoA/ROCK in MSCs induces matrix metalloproteinase-3-mediated CTGF cleavage, resul

71 adenocarcinoma with a concurrent increase of matrix metalloproteinase 7 (MMP7) expression in mouse pr

72 Expression of matrix metalloproteinase 7 (MMP7), an AP-1 target, was a

73 four serum biomarkers (surfactant protein D, matrix metalloproteinase 7, CA19-9, and CA-125) that wer

74 A biomarker signature composed of matrix metalloproteinase 7, pulmonary and activation-reg

75 n to myeloperoxidase-dependent activation of matrix metalloproteinase 7.

76 RATIONALE: Matrix metalloproteinase-7 (MMP-7) has been implicated i

77 in compositional analysis with LC-MS/MS, and matrix metalloproteinase-7 (MMP7) were identified as a p

78 fic PCR array assays revealed that WNT5A and matrix metalloproteinase-7 (MMP7) were upregulated by FO

79 h as Bcl-2 (B-cell lymphoma 2), c-Myc, MMP7 (matrix metalloproteinase-7), and cyclin D1in vitro and i

80 C4-Fc (truncated N-cadherin), or deletion of matrix-metalloproteinase-7 (Mmp-7) reduced VSMC apoptosi

81 Matrix metalloproteinase 8 (MMP-8) is a proinflammatory

82 ich corresponded with lower plasma levels of matrix metalloproteinase-8 and soluble E-selectin.

83 Role of matrix metalloproteinase-8 as a mediator of injury in in

84 Inhibition of matrix metalloproteinase-8 improves survival following c

85 , we expand our understanding of the role of matrix metalloproteinase-8 in sepsis by using an adoptiv

86 Intestine-derived matrix metalloproteinase-8 is a critical component of se

87 inal implantation, found that mice receiving matrix metalloproteinase-8 null intestine had a survival

88 when compared with wild-type mice receiving matrix metalloproteinase-8 null marrow, suggesting that

89 In our adoptive transfer experiments, matrix metalloproteinase-8 null mice receiving wild-type

90 model, no survival advantage was seen among matrix metalloproteinase-8 null mice.

91 Clinically, median matrix metalloproteinase-8 serum concentrations were hig

92 ion and puncture to test the hypothesis that matrix metalloproteinase-8-containing myeloid cells are

93 lloproteinase-8 null marrow, suggesting that matrix metalloproteinase-8-containing myeloid cells are

94 is was associated with decreased circulating matrix metalloproteinase 9 (MMP-9) and increased circula

95 ar junctions concurrently with expression of matrix metalloproteinase 9 (MMP-9), a marker of fast MNs

96 Cathepsin B increased the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved i

97 splayed a high level of enzymatically active matrix metalloproteinase 9 (MMP-9), and were capable of

98 autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 rel

99 cipal H3NT protease of osteoclastogenesis is matrix metalloproteinase 9 (MMP-9).

100 llagen I were reduced as was the activity of matrix metalloproteinase 9 (MMP-9).

101 Matrix metalloproteinase 9 (MMP9) contributes to this pr

102 (fgf8a) expression and positively regulates matrix metalloproteinase 9 (mmp9) expression.

103 Matrix metalloproteinase 9 (MMP9) is a member of a large

104 Matrix metalloproteinase 9 (MMP9) is expressed in teeth

105 Matrix metalloproteinase 9 (MMP9) mRNA, which encodes a

106 Only matrix metalloproteinase 9 (MMP9) was validated; in pre-

107 Lung matrix metalloproteinase 9 and 2 activities increased, w

108 increased levels and activity of circulating matrix metalloproteinase 9 and elevated angiostatin leve

109 It is a major inducer of matrix metalloproteinase 9 and is selectively toxic for

110 lease of the granules' contents, measured as matrix metalloproteinase 9 and neutrophil elastase activ

111 ltration, glutathione-synthesizing capacity, matrix metalloproteinase 9 expression and neointimal smo

112 Neointimal SMC proliferation and medial SMC matrix metalloproteinase 9 expression were not altered b

113 nt decrease in the amount of neutrophils and matrix metalloproteinase 9 in the tissues, and the mitig

114 Matrix metalloproteinase 9 testing in DED is a valuable

115 as myeloperoxidase, neutrophil elastase, and matrix metalloproteinase 9, activates macrophages throug

116 ues from symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 cal

117 extend this work to show that in addition to matrix metalloproteinase 9, hypoxia-inducible factor 1al

118 Matrix metalloproteinase 9, metalloproteinase inhibitor

119 A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D,

120 press CHIT activity and enhance secretion of matrix metalloproteinase 9.

121 .9 vs 3753.2 +/- 1106.0 pg/mL, P = .03), and matrix metalloproteinase-9 (101 515.6 +/- 37 088.4 vs 14

122 he objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomark

123 e have investigated the possible function of matrix metalloproteinase-9 (MMP-9) in alcohol addiction

124 ranscription factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these ce

125 ta1), collagen deposition, and inhibition of matrix metalloproteinase-9 (MMP-9) secretion.

126 molecules (VCAM-1 and ICAM-1, respectively), matrix metalloproteinase-9 (MMP-9), tumor necrosis facto

127 acological inhibition or genetic ablation of matrix metalloproteinase-9 (MMP-9).

128 In addition, PKal inhibition reduced matrix metalloproteinase-9 activity in brain following s

129 nt, including increases in the following: i) matrix metalloproteinase-9 and proinflammatory mediator

130 T cells display helper function for monocyte matrix metalloproteinase-9 and tissue factor production

131 on of beta2GPI-specific T cells for monocyte matrix metalloproteinase-9 and tissue factor production,

132 in-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reducti

133 tracellular matrix remodeling is mediated by matrix metalloproteinase-9 expressed in macrophages with

134 Osteopontin and matrix metalloproteinase-9 were confirmed inside EV.

135 n matrix-degrading proteases cathepsin S and matrix metalloproteinase-9, and systemic serum amyloid A

136 uld be attributed to changes in TGF-beta and matrix metalloproteinase-9, the downstream effectors of

137 nism involving the PI3K/AKT/mTOR pathway and matrix metalloproteinase-9.

138 nd label-free detection of recombinant human matrix metalloproteinases-9 (MMP-9), which has been asso

139 itamin C also restricts the up-regulation of matrix-metalloproteinase-9, the major lung protease invo

140 ion, proinflammatory cytokine synthesis, and matrix metalloproteinase activation.

141 reover, aortas from XY females had augmented matrix metalloproteinase activity and increased oxidativ

142 However, intra-alveolar matrix metalloproteinase activity and levels of the matr

143 We found that matrix metalloproteinase activity is not required for ma

144 y understood pathogenesis in which increased matrix metalloproteinase activity might play an importan

145 egenerative disorders also display increased matrix metalloproteinase activity that contribute to neu

146 tralization of EDPs reduced aortic dilation, matrix metalloproteinase activity, and proinflammatory c

147 ) to N-methyl-D-aspartate (NMDA) ratios, and matrix metalloproteinase activity.

148 red pathogenic mechanisms involving elevated matrix metalloproteinase activity.

149 and caries could be detected using an active matrix metalloproteinase (aMMP)-8 chairside test in Finn

150 tifies an unexpected class of proteases, the matrix metalloproteinase and ADAM families, as potential

151 ormations upon interacting with integrins or matrix metalloproteinase and DNA deformations upon prote

152 transforming growth factor-beta, arginase-1, matrix metalloproteinase and vascular endothelial growth

153 induced a set of disease markers, including matrix metalloproteinases and activated NF-kappaB, hereb

154 migration, including increased expression of matrix metalloproteinases and activation of the c-MET ty

155 These immune cells secrete proteases such as matrix metalloproteinases and cathepsins that contribute

156 terations in matrix remodeling proteins (eg, matrix metalloproteinases and tissue inhibitor of metall

157 Further, expression and activity of matrix metalloproteinases are differentially regulated b

158 ar mediators, we identified TGF-beta and the matrix metalloproteinases as therapeutic targets whose m

159 TGN that controls constitutive secretion of matrix metalloproteinase cargo.

160 metalloproteinase activity and levels of the matrix metalloproteinase cleavage product soluble recept

161 vated protein kinase (MAPK), down-regulating matrix metalloproteinases, collagen, and IL6 secretion f

162 Drosophila ovulation, a process involving a matrix metalloproteinase-dependent follicle rupture.

163 Thus, matrix metalloproteinase-directed processing of PTHrP di

164 ckdown of Galpha13 decreased membrane type 1 matrix metalloproteinase-driven proteolytic invasion in

165 od to track cell invasion by membrane type 1 matrix metalloproteinase-expressing cancer cells.

166 trols vascular endothelial growth factor and matrix metalloproteinase expression in CD133(+) stem cel

167 Transforming growth factor-beta, matrix metalloproteinase expression, and cellular prolif

168 bnormalities in fibrillin-1 accumulation and matrix metalloproteinase expression.

169 1-integrin knockouts, and with inhibition of matrix metalloproteinases, extracellular enzymes that ge

170 olytic enzymes (eg, integrin alphavbeta3 and matrix metalloproteinases), have proven effective in pre

171 Furthermore, inhibiting matrix metalloproteinases in ACM reversed ACM's effect o

172 L-1beta- and TNF-alpha-induced expression of matrix metalloproteinases in both mouse and human chondr

173 Induction of matrix metalloproteinases in melanoma cells by longwave

174 Extracellular matrix metalloproteinase inducer (EMMPRIN, CD147) is a t

175 unct in periodontal treatment because of its matrix metalloproteinase inhibition properties.

176 ibiting ectodomain shedding of Dsg2 with the matrix metalloproteinase inhibitor GM6001 resulted in ac

177 lso were accelerated with the broad-spectrum matrix metalloproteinase inhibitor Marimastat, which may

178 hat myeloma cells express high levels of the matrix metalloproteinase MMP-13 and determined that MMP-

179 to decreased delivery of the membrane-bound matrix metalloproteinase MMP-14 to the plasma membrane.

180 g1l, gilz, and socs3, and development genes, matrix metalloproteinases mmp-9 and mmp-13, while cortis

181 d-Src, phosphorylated-FAK, and expression of matrix metalloproteinase (MMP) -2, MMP-9 and vimentin.

182 lage matrix is accompanied by an increase in matrix metalloproteinase (MMP) 13, partially because of

183 ascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) 13.

184 tic fibrosarcoma oncogene ortholog B (MAFB), matrix metalloproteinase (MMP) 2, and MMP14, respectivel

185 and temporal changes in immunoexpression of matrix metalloproteinase (MMP) 3/9 and caspase 3 were de

186 t learning involves the extracellular enzyme matrix metalloproteinase (MMP) 9.

187 As dysregulation of matrix metalloproteinase (MMP) activity is associated wi

188 Excessive matrix metalloproteinase (MMP) activity is emerging as a

189 Notably, matrix stiffness up-regulates matrix metalloproteinase (MMP) activity, and inhibiting

190 ession inhibits HCAEC migration and secreted matrix metalloproteinase (MMP) activity.

191 leakage was preceded by rapid activation of matrix metalloproteinase (MMP) at pericyte somata, which

192 vatives selectively inhibit AEP and suppress matrix metalloproteinase (MMP) cleavage, leading to the

193 Several members of the matrix metalloproteinase (MMP) family control a range of

194 tion in Cyp26 deficient embryos, attenuating matrix metalloproteinase (MMP) function can rescue both

195 fy an association between a variant within a Matrix metalloproteinase (MMP) gene member, MMP20, and 1

196 this model, we discovered that induction of matrix metalloproteinase (MMP) genes by the WNT/beta-cat

197 In contrast, use of a broad-spectrum matrix metalloproteinase (MMP) inhibitor (GM6001) to blo

198 Using matrix metalloproteinase (MMP) inhibitors and cell incor

199 The design of selective matrix metalloproteinase (MMP) inhibitors that also poss

200 cesses by stimulating interleukin (IL)-6 and matrix metalloproteinase (MMP) release.

201 lular proteases and found that inhibition of matrix metalloproteinase (MMP)- and a disintegrin and me

202 ransforming growth factor beta-1 (p = 0.04), matrix metalloproteinase (MMP)-1 (p = 0.03), MMP-2 (p =

203 dial collagen's resistance to degradation by matrix metalloproteinase (MMP)-1 and interstitial accumu

204 on rate, extremely upregulated expression of matrix metalloproteinase (MMP)-1/2/9 genes compared with

205 this study, we identified elevated levels of matrix metalloproteinase (MMP)-12 in gingival tissue of

206 Matrix metalloproteinase (MMP)-12 plays a key role in th

207 Matrix metalloproteinase (MMP)-13 is a major contributor

208 ctivities in the extracellular matrix by the matrix metalloproteinase (MMP)-14 have been implicated i

209 cer-derived cells, and increases activity of matrix metalloproteinase (MMP)-2 and 9.

210 s factor (TNF)-alpha, nitric oxide (NO), and matrix metalloproteinase (MMP)-2 and tissue inhibitor of

211 Matrix metalloproteinase (MMP)-3 expression in CTGF-deli

212 Plasma surfactant protein (SP)-D > 31 ng/ml, matrix metalloproteinase (MMP)-7 > 1.75 ng/ml, and osteo

213 okine induced by interferon-gamma (MIG), and matrix metalloproteinase (MMP)-8 in serum and saliva fro

214 Matrix metalloproteinase (MMP)-8 is a major destructive

215 Salivary CSF-1, IL-34, and matrix metalloproteinase (MMP)-8, a biomarker candidate

216 Whole salivary interleukin (IL)-1beta, IL-6, matrix metalloproteinase (MMP)-8, and MMP-9 levels among

217 This study evaluates levels of matrix metalloproteinase (MMP)-8, MMP-9, and tissue inhi

218 ssion in the tumor cells negatively affected matrix metalloproteinase (MMP)-9 gene expression.

219 Matrix metalloproteinase (MMP)-9 is a key enzyme that re

220 to investigate levels of salivary and serum matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO),

221 nolabeling, and suppressed the activation of matrix metalloproteinase (MMP)-9-mediated gelatinolysis.

222 own was driven by Mtb-dependent secretion of matrix metalloproteinase (MMP)-9.

223 P mediates ordered proteolytic processing of matrix metalloproteinase (MMP)-derived collagen cleavage

224 e-like traits, including rounded morphology, matrix metalloproteinase (MMP)-independent migration, an

225 that the intestine is an important source of matrix metalloproteinase (MMP)8 during intestinal injury

226 such as the translocator protein (TSPO) and matrix metalloproteinases (MMP), may serve as specific i

227 ation through a 3D extracellular matrix in a matrix metalloproteinases (MMP)-dependent fashion.

228 sses of proteases: plasmin, cathepsin L, and matrix metalloproteinases (MMP-2 and MMP-9).

229 xtracellular matrix remodelling regulated by matrix-metalloproteinase (MMP) inducer (CD147) is a cruc

230 RATIONALE: Macrophage elastase (matrix metalloproteinase [MMP]-12) is a potent protease

231 Concentrations of active enzymes (matrix metalloproteinase [MMP]-8, elastase, and sialidas

232 the stress kinase JNK and production of the matrix metalloproteinase MMP1.

233 on the mobilization of the membrane-anchored matrix metalloproteinases MMP14 (MT1-MMP) and MMP15 (MT2

234 se-8, neutrophil elastase, legumain, and two matrix metalloproteinases (MMP2 and MMP9), we demonstrat

235 s, including androgen receptor, estrogen and matrix metalloproteinase MMP9 and promoted the metastati

236 y products of individual leukocytes, such as matrix metalloproteinases (MMPs) and a disintegrin and m

237 ammatory skin disorder where upregulation of matrix metalloproteinases (MMPs) and antimicrobial pepti

238 en hydrogen sulfide (H2S), microRNAs (miRs), matrix metalloproteinases (MMPs) and poly-ADP-ribose-pol

239 he expression of adrenoreceptors, aggrecans, matrix metalloproteinases (MMPs) and RANKL by chondrocyt

240 ing cued reinstatement depends on activating matrix metalloproteinases (MMPs) and selective chemogene

241 Matrix metalloproteinases (MMPs) are a family of secrete

242 ligand (RANKL) and released enzymes such as matrix metalloproteinases (MMPs) are among the factors i

243 Matrix metalloproteinases (MMPs) are central to cancer d

244 Matrix metalloproteinases (MMPs) are extracellular prote

245 Matrix Metalloproteinases (MMPs) are thought to play an

246 Matrix metalloproteinases (MMPs) are upregulated in CAVD

247 Under pathological conditions, matrix metalloproteinases (MMPs) can disrupt the BBB thr

248 Matrix metalloproteinases (MMPs) contribute to conventio

249 Matrix metalloproteinases (MMPs) contribute to the break

250 for degradation of the extracellular matrix, matrix metalloproteinases (MMPs) exhibit broad potential

251 Drug candidates against matrix metalloproteinases (MMPs) failed in the clinic in

252 To many of us in the field, working on matrix metalloproteinases (MMPs) has felt like riding a

253 Matrix metalloproteinases (MMPs) have been implicated in

254 lates the expression and activity of several matrix metalloproteinases (MMPs) in cell lines and in th

255 Aberrant activation of matrix metalloproteinases (MMPs) is a common feature of

256 been made to impart sensitivity to specific matrix metalloproteinases (MMPs) known to be overexpress

257 Matrix metalloproteinases (MMPs) play a key role in abdo

258 Matrix metalloproteinases (MMPs) play a key role in many

259 Matrix metalloproteinases (MMPs) play important roles in

260 Matrix metalloproteinases (MMPs) play key roles in the d

261 nd remodeling of the extracellular matrix by matrix metalloproteinases (MMPs) plays important roles i

262 Extracellular matrix metalloproteinases (Mmps) regulated by secreted t

263 Activated proteases such as matrix metalloproteinases (MMPs) secreted from cancer ce

264 In contrast to mammalian matrix metalloproteinases (MMPs) that play important rol

265 istant to proteolysis, requiring specialized matrix metalloproteinases (MMPs) to initiate its remodel

266 matrices in the human body is controlled by matrix metalloproteinases (MMPs), a family of more than

267 gate the levels of neutrophil elastase (NE), matrix metalloproteinases (MMPs), and myeloperoxidase (M

268 which controlled by pro-fibrolytic enzymes, matrix metalloproteinases (MMPs), and pro-fibrotic cytok

269 Enzymes that modify the ECM, such as matrix metalloproteinases (MMPs), have long been recogni

270 which might be related to downregulation of matrix metalloproteinases (MMPs), i.e., MMP-9 and MMP-2,

271 and mouse studies have implicated roles for matrix metalloproteinases (MMPs), particularly macrophag

272 ression of fibronectin- and laminin-specific matrix metalloproteinases (MMPs), particularly MMP-3, wa

273 zes conserved molecular mechanisms including matrix metalloproteinases (Mmps), steroid signaling, and

274 Tumor cell invasion and the expression of matrix metalloproteinases (MMPs), which are required for

275 Monocytes secrete matrix metalloproteinases (MMPs), which have key roles i

276 e synthesis of proinflammatory cytokines and matrix metalloproteinases (MMPs), which play a role in e

277 Platelets contain and release several matrix metalloproteinases (MMPs).

278 ing extracellular matrix (ECM) remodeling by matrix metalloproteinases (MMPs).

279 truction via the induction and activation of matrix metalloproteinases (MMPs).

280 trix components and their regulators such as matrix metalloproteinases (MMPs).

281 failed to achieve selectivity against human matrix metalloproteinases (MMPs).

282 (GM6001) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does not ful

283 ited impaired trafficking of membrane type 1 matrix metalloproteinase (MT1-MMP) and EGF receptor (EGF

284 the pericellular collagenase membrane-type 1 matrix metalloproteinase (MT1-MMP) and membrane-mimickin

285 We here report that membrane type-1 matrix metalloproteinase (MT1-MMP) deficient mice have r

286 Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a membrane-bound M

287 Membrane type 1-matrix metalloproteinase (MT1-MMP) is associated with en

288 Migratory cells translocate membrane type-1 matrix metalloproteinase (MT1-MMP) to podosomes or invad

289 on of invadopodia containing membrane type I matrix metalloproteinase (MT1-MMP).

290 Membrane type 1 matrix metalloproteinase (MT1-MMP, MMP-14) is a transmem

291 rcinoma cells is mediated by membrane type 1-matrix metalloproteinase (MT1-MMP/MMP14), the main invad

292 i-inflammatory cells, and macrophage-derived matrix metalloproteinases regulate fibrin and collagen t

293 In contrast, the matrix metalloproteinase/TACE (tumor necrosis factor-alp

294 genesis of rosacea is unclear, but increased matrix metalloproteinase target tissue activity appears

295 tant for integrin activation and delivery of matrix metalloproteinases: through the upstream recruite

296 , 7, 8, 9, 12), MPO, and tissue inhibitor of matrix metalloproteinase (TIMP)-1 were analyzed using mu

297 the mature PTHrP1-36 hormone is processed by matrix metalloproteinases to yield a stable product, PTH

298 n of effectors of degeneration such as three matrix metalloproteinases underscores the data's pathoph

299 of proinflammatory cytokines, chemokines and matrix metalloproteinases, which together facilitated T

300 that simultaneous modulation of TGF-beta and matrix metalloproteinases would be more effective in tre